Form 4: Insmed CFO Sara Bonstein Reports Stock Transactions Following PSU Vesting

Insmed's CFO, Sara Bonstein, reports acquiring shares through vested Performance Stock Units (PSUs) and subsequently selling a portion to cover tax obligations.

Summary

• On February 5, 2025, Sara Bonstein, CFO of Insmed Inc., acquired 65,033 shares of common stock upon the vesting of Performance Stock Units (PSUs) granted on January 6, 2022.
• The PSUs vested due to the achievement of applicable performance and service conditions.
• On February 6, 2025, Ms. Bonstein sold 28,390 shares of common stock at a weighted average price of $80.9 per share, with prices ranging from $80.57 to $81.43.
• The sale was to satisfy tax withholding obligations related to the vesting of the PSUs and to cover broker fees.
• Following these transactions, Ms. Bonstein beneficially owns 155,506 shares of Insmed Inc. common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The vesting of PSUs is positive, indicating performance goals were met. The sale of shares is likely for tax purposes, which is a normal occurrence, but could be perceived negatively by some investors.

Positives

• The vesting of PSUs indicates that performance and service conditions were met, which could be viewed positively.

Negatives

• The sale of shares, even for tax purposes, could be interpreted negatively by some investors, although it's a common practice.

Risks

• The document itself doesn't highlight any specific risks, but the sale of shares by a key executive could create short-term market uncertainty.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. Investors often monitor these transactions for insights into management's confidence in the company's future prospects. Sales to cover tax obligations are generally viewed as routine.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units (RSUs) or PSUs that vest over time.
• The vesting and subsequent sale of shares to cover taxes are standard practices across many publicly traded companies, including those in the biotechnology sector like Amgen, Gilead Sciences, and Biogen.
• The specific vesting terms and conditions, as well as the volume of shares sold, can vary significantly based on company performance and individual compensation agreements.

Stakeholder Impact

• The transaction could have a minor impact on shareholders due to the sale of shares, but it's unlikely to be significant.

Key Dates